SEHK:1530Biotechs
3SBio (SEHK:1530) Trailing 48% Net Margin Challenges Bearish Earnings Decline Narrative
3SBio (SEHK:1530) has just posted its FY 2025 first half results, with revenue of ¥4.4b and basic EPS of ¥0.57, while trailing twelve month EPS stands at ¥3.51 on revenue of ¥17.7b. This points to a period where profitability has been heavily supported by strong net income levels. Looking back, the company has seen half year revenue move from ¥4.39b and EPS of ¥0.45 in 2024 H1 to ¥4.36b and EPS of ¥0.41 in 2024 H2, before landing at the current ¥4.36b and ¥0.57 in 2025 H1. This sets up a...